Invariant natural killer T (iNKT) cells play an important role in the progression of chronic inflammatory diseases of the vasculature, including atherosclerosis and lupus-associated vascular disease. The overall goal of this application is to obtain in depth understanding of the in vivo mechanisms underlying iNKT cell activation by various stimuli and to utilize this information for the development of better therapeutic approaches of chronic inflammatory diseases of the vascular system. The investigators of this application have shown that the iNKT cell antigen -galactosylceramide (-GalCer) can prevent the development of lupus-like disease in mice, but paradoxically exacerbates the development of atherosclerosis in susceptible animals. Despite the impact of - GalCer treatment on a variety of disease processes, our understanding of the response of iNKT cells themselves to various stimuli is limited. Recent studies from the PI's laboratory have demonstrated that in vivo activation of iNKT cells with -GalCer results in a dynamic response by these cells that is characterized by surface receptor downmodulation, expansion, cytokine production, cross-talk with other cells, homeostatic contraction, and acquisition of an anergic phenotype. Guided by these preliminary findings, studies in this application will test the overall hypothesis that iNKT cells, by responding to a variety of endogenous and exogenous molecular patterns, can modulate the progression of chronic inflammatory diseases of the vascular system. This hypothesis will be tested in the following integrated Specific Aims.
Aim 1 will investigate the mechanisms by which iNKT cells respond to endogenous and exogenous molecular patterns that modulate the progression of inflammatory vascular disease. These studies will be focused on identifying iNKT cell stimuli that can induce iNKT cell anergy and to investigate the role of co-stimulatory receptors in the acquisition of this anergic phenotype.
Aim 2 will investigate the impact of iNKT cell anergy on the capacity of these cells to modulate chronic inflammatory vascular disease. A major goal of this aim will be to identify iNKT cell-based treatment modalities that can protect susceptible mice against the development of both lupus-like autoimmunity and atherosclerosis.
Aim 3 will investigate the response of human iNKT cells to glycolipid antigens and microbial products, which will permit validation of the mouse studies. Completion of the work described in this proposal will provide novel insight into fundamental iNKT cell biology and the immunomodulatory activities of iNKT cells during the progression of vascular diseases. These studies will build a foundation of knowledge upon which safe and effective iNKT cell-based therapies for lupus, atherosclerosis and other chronic inflammatory diseases of the cardiovascular system can be developed.

Public Health Relevance

The proposed studies will provide a better understanding of the mechanism by which a particular cell type of the immune system, the iNKT cell, influences blood vessel diseases such as atherosclerosis and lupus- associated vascular disease. The results from these proposed studies will be instrumental for the development of novel preventive measures and therapies for blood vessel diseases and their complications (e.g., heart disease and stroke).

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Gao, Yunling
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Schools of Medicine
United States
Zip Code
Van Kaer, Luc; Algood, Holly M Scott; Singh, Kshipra et al. (2014) CD8??? innate-type lymphocytes in the intestinal epithelium mediate mucosal immunity. Immunity 41:451-64
Wu, Lan; Parekh, Vrajesh V; Hsiao, Joseph et al. (2014) Spleen supports a pool of innate-like B cells in white adipose tissue that protects against obesity-associated insulin resistance. Proc Natl Acad Sci U S A 111:E4638-47
Parekh, Vrajesh V; Wu, Lan; Olivares-Villagomez, Danyvid et al. (2013) Activated invariant NKT cells control central nervous system autoimmunity in a mechanism that involves myeloid-derived suppressor cells. J Immunol 190:1948-60
Wu, Lan; Van Kaer, Luc (2013) Contribution of lipid-reactive natural killer T cells to obesity-associated inflammation and insulin resistance. Adipocyte 2:12-16
Van Kaer, Luc; Rabacal, Whitney A S; Scott Algood, Holly M et al. (2013) In vitro induction of regulatory CD4+CD8?+ T cells by TGF-?, IL-7 and IFN-?. PLoS One 8:e67821
Andoh, Yasuhiro; Ogura, Hisako; Satoh, Masashi et al. (2013) Natural killer T cells are required for lipopolysaccharide-mediated enhancement of atherosclerosis in apolipoprotein E-deficient mice. Immunobiology 218:561-9
Parekh, Vrajesh V; Wu, Lan; Boyd, Kelli L et al. (2013) Impaired autophagy, defective T cell homeostasis, and a wasting syndrome in mice with a T cell-specific deletion of Vps34. J Immunol 190:5086-101
Wu, Lan; Parekh, Vrajesh V; Gabriel, Curtis L et al. (2012) Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice. Proc Natl Acad Sci U S A 109:E1143-52
Van Kaer, Luc (2011) Glatiramer acetate for treatment of MS: regulatory B cells join the cast of players. Exp Neurol 227:19-23
Oeser, James K; Parekh, Vrajesh V; Wang, Yingda et al. (2011) Deletion of the G6pc2 gene encoding the islet-specific glucose-6-phosphatase catalytic subunit-related protein does not affect the progression or incidence of type 1 diabetes in NOD/ShiLtJ mice. Diabetes 60:2922-7

Showing the most recent 10 out of 20 publications